The Pulse of the MedTech Industry Report 2024 from EY is now available for download! While research shows that the MedTech industry is still growing, it is increasingly walking a narrow path between converging top-line and bottom-line pressures. With deep insights from EY thought leaders and perspectives from top MedTech executives on the current financing environment, capital efficiency viewpoints, what’s next in MedTech financing, and the future of innovation, the EY analysis on the state of the industry leaves no stone unturned.
Click here for details: www.ey.com/pulse
Related Reading
News / Global & Trade / Government & Legislative Affairs / Health Access / Supply Chain / Tariffs
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
September 25, 2025
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/12
September 12, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/5
September 5, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/22
August 22, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/15
August 19, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
August 12, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/25
July 25, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/18
July 18, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.